VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 12, 2008) - Representatives of ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") attended the 4th Canadian Microbicides Symposium held in Ottawa on January 28, 2008. A round table discussion on the current status of microbicide research revealed that no microbicidal products available to date have proven to be effective against the spread of HIV and AIDS, a conclusion that is supported by statements from the World Health Organization. After participating in the symposium, the ALDA team met with Senator Celine Hervieux-Payette and the Hon. Robert Thibault, Member of Parliament. In these meetings, discussions took place about Canada's position domestically and on the global stage of HIV and AIDS prevention and how ALDA might contribute to this effort. A meeting was also held with Health Canada to determine the best path to follow to obtain regulatory approval of T36(R) Microbicide. By attending and participating in the symposium and the subsequent meetings, ALDA was provided an opportunity to introduce T36(R) Microbicide to individuals and agencies in the federal government and the private sector that are active in the area of combating HIV and AIDS. Dr. Terrance Owen, President & CEO, states, "Other organizations working in the field of HIV and AIDS prevention have discovered that the development of a successful microbicide is fraught with difficulties. Having knowledge of these complex issues, we have been cautious about straying from our focus on infection-control treatments to pursue the more complicated field of preventative microbicides. However, our attendance at the recent symposium in January and the personal meetings thereafter has convinced us that T36(R) Microbicide is a promising candidate for further study in preventing the spread of HIV and AIDS. Dr. Brian Conway, who is a member of ALDA's Scientific Advisory Board and is also Co-Chair of The Ministerial Advisory Council on the Federal Initiative to Address HIV/AIDS in Canada has agreed to assist us with the design and completion of preliminary clinical trials." About T36(R) Microbicide Gel T36(R) Microbicide Gel is a personal lubricant that is designed to prevent the spread of HIV and other Sexually Transmitted Infections ("STI's"). It contains infection-control ingredients in relatively low concentrations that act synergistically to disrupt the physical structure of microbes rather than interfering with their metabolic pathways. The competitive advantage is its ability to kill STI-causing organisms while preventing microbial resistance, side effects or toxicity. About ALDA Pharmaceuticals Corp. ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release